Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.63 |
| ▸ | LCK | P06239 | 5/20 | 0.63 |
| ▸ | BRAF | P15056 | 7/20 | 0.58 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | LYN | P07948 | 3/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | HCK | P08631 | 1/20 | 0.54 |
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 5/20 | 0.52 |
| ▸ | BCR | P11274 | 4/20 | 0.52 |
| ▸ | RAF1 | P04049 | 5/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940107 | 0.85 | KDR (0.57) | LCKBRAFKDRLYNSRC | |
| SCHEMBL2938813 | 0.85 | KDR (0.57) | LCKBRAFKDRLYNSRC | |
| SCHEMBL2942453 | 0.85 | RAF1 (0.63) | BRAFRAF1 | |
| SCHEMBL2940451 | 0.83 | ABL1 (0.59) | MAPK14LCKBRAFKDRSRC | |
| SCHEMBL2942477 | 0.82 | BRAF (0.61) | BRAFKDRABL1BCRKIT | |
| SCHEMBL2945905 | 0.82 | BTK (0.58) | LCKBRAFKDRLYNSRC | |
| SCHEMBL2945922 | 0.81 | BRAF (0.59) | BRAFKDRABL1BCRKIT | |
| SCHEMBL2941258 | 0.81 | ABL1 (0.55) | LCKBRAFKDRLYNSRC | |
| SCHEMBL14107966 | 0.80 | LCK (0.81) | MAPK14LCKBRAFKDRSRC | |
| SCHEMBL2944614 | 0.80 | KIT (0.62) | MAPK14LCKBRAFKDRLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635835-B1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | claimed |
| EP-1635835-B1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | NOVARTIS AG (CH) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK14 131/4885LCK 289/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.